[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360347-105":59,"doc-detail-360347-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","an-ldh-based-prognostic-model-for-extensive-stage-small-cell-lung-cancer-patients-treated-with-chemo-immunotherapy-and-consolidative-thoracic-radiotherapy","An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy","","Lactate dehydrogenase (LDH) is evaluated as a practical prognostic biomarker for extensive-stage small-cell lung cancer (ES-SCLC) patients receiving chemo-immunotherapy followed by consolidative thoracic radiotherapy. A retrospective cohort of 81 stage III–IV cases (2019–2025) collects clinical variables and blood biomarkers, with survival assessed using Kaplan–Meier curves and Cox proportional hazards models. Serum LDH is identified as an independent marker, patients with LDH >250 U/L showing poorer overall survival. A nomogram integrating LDH, AJCC stage, SII, and immunotherapy status estimates 1- and 2-year OS and demonstrates moderate discriminative performance using time-dependent ROC.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-ldh-based-prognostic-model-for-extensive-stage-small-cell-lung-cancer-patients-treated-with-chemo-immunotherapy-and-consolidative-thoracic-radiotherapy/360347/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-ldh-based-prognostic-model-for-extensive-stage-small-cell-lung-cancer-patients-treated-with-chemo-immunotherapy-and-consolidative-thoracic-radiotherapy/360347.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical question does the study address for ES-SCLC patients?","Question",{"text":113,"@type":114},"It tests whether serum LDH has prognostic significance for overall survival in extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was LDH used in the prognostic analysis?",{"text":118,"@type":114},"Serum LDH was identified as an autonomous prognostic marker via multivariate analysis and then categorized using a clinical threshold of 250 U/L for deeper study.",{"name":120,"@type":111,"acceptedAnswer":121},"What model does the study propose and what outcome does it predict?",{"text":122,"@type":114},"The study develops a prognostic nomogram that estimates 1- and 2-year overall survival by incorporating LDH, AJCC stage, systemic immune-inflammation index (SII), and immunotherapy status.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360347,1790194397,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Original Research PUBLISHED 20 May 2026  \nDOI 10.3389/fendo.2026.1836555  \nOPEN ACCESS  \nEDITED BY  \nYanxiang Zhang,  \nThe First Afﬁliated Hospital of Soochow University, China  \nREVIEWED BY  \nGui-Qi Zhu,  \nFudan University, China Xinyu Liang,  \nQuzhou City People’s Hospital, China  \n*CORRESPONDENCE  \nYuwen Zhou  \n[drzhouyuwen@163.com](drzhouyuwen@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 23 March 2026  \nREVISED 18 April 2026  \nACCEPTED 27 April 2026  \nPUBLISHED 20 May 2026  \nCITATION  \nZhao Y, Zou Y, Zhang S, Zhang Y,  \nZhou X, Li S and Zhou Y (2026) An LDHbased prognostic model for extensivestage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy. Front. Endocrinol. 17:1836555 .  \ndoi: 10.3389/fendo.2026.1836555  \nCOPYRIGHT  \n© 2026 Zhao, Zou, Zhang, Zhang, Zhou, Li and Zhou. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAn LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative  \nthoracic radiotherapy  \nYunuo Zhao 1†, Yuchi Zou 2†, Shengxin Zhang 1†, Yu Zhang 1, Xueyan Zhou 1, Shen Li 1 and Yuwen Zhou 3*  \n1 Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 2Outpatient Department, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 3 Department of Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China  \nBackground: Extensive-stage small-cell lung cancer (ES-SCLC) is a highly aggressive malignancy with poor long-term survival despite multimodal therapy . Endocrine and metabolic alterations have been increasingly recognized as contributors to tumor progression and potential prognostic indicators. Lactate dehydrogenase (LDH), a readily available bio marker reﬂecting tumor metabolic activity, has been associated with outcomes in various cancers. However, its prognostic signiﬁcance in ES-SCLC patients receiving combined chemo-immunotherapy and consolidative thoracic radiotherapy remains unclear.  \nMethods: Between 2019 and 2025, 81 stage III-IV ES-SCLC cases treated with chemo-immunotherapy and subsequent consolidative chest radiation were retrospectively reviewed. Clinical variables and blood biomarkers were collected. To evaluate prognosis, we employed Kaplan-Meier curves and Cox proportional hazards modeling. Having identiﬁed serum LDH as an autonomous prognostic marker through multivariate analysis, we categorized it using a clinical threshold of 250 U/L for in-depth study. Subsequently, we developed a prognostic nomogram for estimating OS at 1-and 2-years. Time-dependent ROC analysis conducted at the 12-and 24-mo nth marks was utilized to evaluate the model ’s discriminative power.  \nResults: In total, 81 patients were included in the ﬁnal analysis. Multivariable Cox regression demonstrated that serum LDH was independently associated with poorer overall survival (hazard ratio [HR] 1.006 per 1 U increase, 95% conﬁdence interval [CI] 1 .003–1. 009; p \u003C 0 . 001) . Kaplan–Meier analysis using a clinically deﬁned LDH threshold demonstrated signiﬁcantly reduced overall survival among patients with elevated LDH levels (>250 U/L) compared with those with lower LDH values (≤250 U/L; p=0 . 0012) . The prognostic nomogram incorporating LDH, AJCC stage, the systemic immune-inﬂamma tion index (S II), and immunotherapy status demonstrated moderate discriminative ability, with an area under the curve for OS of 0 .731 at 12 months an","cbCaihbeNd66EE2a","https://ap.wps.com/l/cbCaihbeNd66EE2a","pdf",1974208,11,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Key topics (from introduction)\n## Prognostic heterogeneity and need for biomarkers\n## Current standard of care and evolving treatment context","[{\"question\":\"What clinical question does the study address for ES-SCLC patients?\",\"answer\":\"It tests whether serum LDH has prognostic significance for overall survival in extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy.\"},{\"question\":\"How was LDH used in the prognostic analysis?\",\"answer\":\"Serum LDH was identified as an autonomous prognostic marker via multivariate analysis and then categorized using a clinical threshold of 250 U/L for deeper study.\"},{\"question\":\"What model does the study propose and what outcome does it predict?\",\"answer\":\"The study develops a prognostic nomogram that estimates 1- and 2-year overall survival by incorporating LDH, AJCC stage, systemic immune-inflammation index (SII), and immunotherapy status.\"}]","An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy | PDF",1790139737,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee37f915fd72505b6e770043594e00ac.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c089f68355244324ba4f3eee51ae4bb1.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc14d56d53043486a1e35c43377f2875.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1b353f06b86c7a45043af562724bbce.webp",980,1385]